2024 年度募集资金存放与使用的专项核查意见 国投证券股份有限公司（以下简称"保荐机构"、"国投证券"）作为哈尔滨三 联药业股份有限公司（以下简称"哈三联"、"公司"）首次公开发行Ａ股股票（以 下简称"首次发行"）的保荐机构，根据《证券发行上市保荐业务管理办法》、《深 圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》、《上市公司监管指引第 2 号—上市公司募集资金管理 和使用的监管要求》等相关规定，对哈三联截至 2024 年 12 月 31 日的募集资金 存放与使用情况进行了核查，具体情况如下： 一、哈三联首次发行募集资金的基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于哈尔滨三联药业股份有限公司首次公开发 行股票的批复》（证监许可[2017]1602 号文）核准，2017 年 9 月 12 日，公司公开 发行人民币普通股（A 股）5,276.67 万股，发行价格为每股 18.07 元，募集资金 总额为人民币 95,349.43 万元，扣除发行费用 5,337.53 万元，本次募集资金净额 为 90,011.90 万元。 以 ...

哈尔滨三联药业股份有限公司 内部控制审计报告 中兴财光华审专字（2025）第 213054 号 内部控制审计报告 中兴财光华审专字（2025）第213054号 哈尔滨三联药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了哈尔滨三联药业股份有限公司（以下简称"哈三联"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是哈三联董事会的责任。 二、注册会计师的责任 2025 年 4 月 23 日 2 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降 低，根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为， ...

哈尔滨三联药业股份有限公司 2024 年度独立董事述职报告 本人作为哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会 独立董事，在任职期间严格按照《公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 法律、法规以及《公司章程》、《独立董事工作制度》等公司制度的相关规定， 严格保持独立董事的独立性和职业操守，认真履行了独立董事的职责，依法合规 地行使了独立董事的权利。本着对全体股东负责的态度，积极参加公司各专门委 员会会议、董事会和股东大会，以审慎的态度发表独立意见，切实维护公司和全 体股东的合法权益。现就本人 2024 年度履职情况说明如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人曾国林，1979 年生，中国国籍，无境外永久居留权。毕业于中国政法大 学，法律硕士，具有律师执业资格。曾任北京万商天勤律师事务所律师，北京中 伦律师事务所律师；现任北京德恒律师事务所合伙人律师。自 2019 年 12 月至 今，任公司独立董事。 （二）独立性说明 担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务，也 未在公司主 ...

哈尔滨三联药业股份有限公司 2024 年度独立董事述职报告 本人作为哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会独 立董事，因个人工作安排于 2024 年 8 月 15 日辞任。在 2024 年任职期间，本人 按照《公司法》《上市公司治理准则》《上市公司独立董事管理办法》等法律、 法规和《公司章程》、《独立董事工作制度》的规定，忠实履行职务，积极出席 相关会议，认真审议董事会各项议案，努力维护公司整体利益，尤其关注社会公 众股股东的合法权益不受损害，较好地发挥了独立董事的独立作用。现将 2024 年本人任职期间履行独立董事职责的情况述职如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人王福胜，1964 年生，中共党员，中国国籍，无境外永久居留权。毕业 于哈尔滨工业大学，管理科学与工程博士。曾任龙建路桥股份有限公司、哈药集 团股份有限公司、哈尔滨中飞新技术股份有限公司、哈尔滨东安汽车动力股份有 限公司、哈尔滨秋林集团股份有限公司独立董事，哈尔滨市城市建设投资集团有 限公司外部董事；现任哈尔滨工业大学管理学院会计系教授、博士生导师，中国 广电黑龙江网络股份有限公司、谷实生物集团股份有限 ...

哈尔滨三联药业股份有限公司 2024 年度独立董事述职报告 作为哈尔滨三联药业股份有限公司（以下简称"公司"）独立董事，本人依据 《公司法》、《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》等法律、法规以及《公司章程》、 《独立董事工作制度》的要求，勤勉尽责地履行独立董事的职责和义务。本人认 真行使公司和股东赋予的权利，积极出席公司相关会议，认真审议公司董事会各 项议案，全面关注公司的经营状况、内部控制的建设情况及董事会决议执行情况， 积极参与公司治理，为公司经营和发展提出合理化的意见和建议。本人于 2024 年 8 月 15 日起担任公司第四届董事会的独立董事，现将本人 2024 年度任职期间 履职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人王栋，1973 年生，中国国籍，无境外永久居留权。毕业于哈尔滨工业大 学，工商管理硕士，注册会计师、高级会计师。曾任中审众环会计师事务所（特 殊普通合伙）合伙人、黑龙江分所负责人。现任中审亚太会计师事务所（特殊普 通合伙）合伙人、黑龙江分所负责人，哈尔滨城市发展投资集团有限公司、哈尔 滨 ...

哈尔滨三联药业股份有限公司 舆情管理制度 第一条 为提高哈尔滨三联药业股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股 价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益， 根据《深圳证券交易所股票上市规则》等相关法律法规、部门规章、规范性文件 和《公司章程》等有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、杂志、电视、广播、网络等媒体对公司进行的负面、不实报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易 价格变动的负面舆情； （二）一般舆情：指除重大舆情之外的其他舆情。 哈尔滨三联药业股份有限公司 舆情管理制度 第一章 总 则 第二章 舆情管理的组织体系 ...

哈尔滨三联药业股份有限公司 2024 年度独立董事述职报告 作为哈尔滨三联药业股份有限公司（以下简称"公司"）独立董事，本人在 2024 年度严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、法规以及 《公司章程》、《独立董事工作制度》的相关规定，恪尽职守、勤勉尽责地履行 自身职责，积极出席公司相关会议，及时了解公司生产经营情况，对重大事项发 表独立、客观的意见，切实维护公司及全体股东的合法权益。现将本人 2024 年 度履职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人刘洪泉，1959 年生，中共党员，中国国籍，无境外永久居留权。毕业 于中欧国际工商学院，工商管理硕士。曾任华瑞制药有限公司董事、总经理兼党 委书记，先声药业集团有限公司首席执行官，无锡凯夫制药有限公司总经理，费 森尤斯卡比（中国）投资有限公司总裁，费森尤斯卡比华瑞制药有限公司董事长； 现任江苏中贸发无锡医药有限公司董事长，无锡凯夫制药有限公司董事，无锡凯 夫科技有限公司执行董事，亿帆医药股份有限公司独立董事。自 2022 年 3 月至 ...

哈尔滨三联药业股份有限公司 董事会对独立董事独立性自查情况的专项报告 经核查独立董事刘洪泉先生、王栋先生、曾国林先生的任职经历以及签署的 相关自查文件等内容，董事会认为上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系。因此，公司独立董事符合 《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事独 立性的相关要求。 哈尔滨三联药业股份有限公司 董事会 2025 年 4 月 23 日 根据《上市公司独立董事管理办法》、《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律 法规的相关规定，哈尔滨三联药业股份有限公司(以下简称"公司")董事会就公 司在任独立董事刘洪泉先生、王栋先生、曾国林先生的独立性情况进行评估并出 具专项意见如下： ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,132,476,522.09, a decrease of 4.58% compared to CNY 1,186,786,001.40 in 2023[16]. - The net profit attributable to shareholders for 2024 was CNY 58,675,175.44, down 20.35% from CNY 73,663,110.90 in 2023[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 73.85% to CNY 53,233,408.45 in 2024 from CNY 30,619,980.53 in 2023[16]. - The net cash flow from operating activities for 2024 was CNY 30,687,788.46, a decline of 14.02% from CNY 35,693,579.98 in 2023[16]. - The total assets at the end of 2024 were CNY 3,800,468,270.17, reflecting a growth of 10.38% from CNY 3,442,984,089.62 at the end of 2023[16]. - The net assets attributable to shareholders at the end of 2024 were CNY 2,160,120,383.68, a slight increase of 0.92% from CNY 2,140,492,171.94 at the end of 2023[16]. - The basic earnings per share for 2024 were CNY 0.19, down 20.83% from CNY 0.24 in 2023[16]. - The diluted earnings per share for 2024 were also CNY 0.19, reflecting the same percentage decrease as the basic earnings per share[16]. - The weighted average return on net assets for 2024 was 2.75%, down from 3.57% in 2023[16]. Revenue Breakdown - The company's total revenue for the four quarters was as follows: Q1: ¥246.82 million, Q2: ¥276.62 million, Q3: ¥315.08 million, Q4: ¥293.95 million, indicating a steady growth trend[20]. - The net profit attributable to shareholders for the four quarters was: Q1: ¥18.79 million, Q2: ¥7.48 million, Q3: ¥14.31 million, Q4: ¥18.09 million, showing fluctuations in profitability[20]. - The net cash flow from operating activities improved significantly in Q4, reaching ¥75.81 million, compared to negative cash flows in the first three quarters[20]. - The pharmaceutical sector generated ¥989,103,863.08, accounting for 87.34% of total revenue, with a year-on-year decline of 13.48%[61]. - The veterinary medicine sector saw a significant increase in revenue to ¥75,198,173.15, up 740.79% from ¥8,943,788.35 in the previous year[61]. Industry Trends - The pharmaceutical industry is experiencing robust growth driven by population aging, improved healthcare systems, and rising health demands, positioning it as a key sector for long-term investment[24]. - The government has implemented a series of reforms in 2024 aimed at enhancing the pharmaceutical sector, including drug innovation and price governance, which are expected to support industry growth[25]. - The national drug procurement policy has led to an average price reduction of over 50% for selected drugs, significantly impacting market dynamics and competition[26]. - The shift from sales-driven to cost-driven strategies in the generic drug market is reshaping the competitive landscape, with companies focusing on cost management and innovation[27]. - The potential market space for the pharmaceutical sector in China remains substantial, despite short-term growth pressures, indicating long-term investment opportunities[24]. Research and Development - The company has established a comprehensive R&D and production system for chemical drug formulations, focusing on innovation and sustainable development[32]. - The company has a diversified product portfolio covering key therapeutic areas, with several products ranking among the top in their respective segments[34]. - The company has implemented an integrated "active pharmaceutical ingredients - formulations" strategy, ensuring drug quality and supporting the growth of its API business[34]. - The company is actively developing new products in the animal health sector, which is a strategic focus since the establishment of Harbin Longjiang Animal Health Biotechnology Co., Ltd. in 2021[37]. - The company is committed to ensuring the accuracy of its financial data and market insights to support strategic decision-making[36]. Market Expansion and Strategy - The company is focusing on expanding its market presence through innovative product development and strategic partnerships in the pharmaceutical and animal health sectors[37]. - The company has 23 generic drug varieties that have passed or are deemed to have passed the quality and efficacy consistency evaluation, with 10 core products selected for national centralized procurement[41]. - The company has established a production base for anti-coccidial raw materials with a fermentation capacity of 360m³, which has passed GMP certification[38]. - The company is focusing on the health consumer goods market, with three main business branches: beauty, medical device dressings, and food products[39]. - The company is expanding its veterinary injection product line with new approvals, including Vitamin C and other formulations[76]. Financial Management - The total operating costs for 2024 amounted to CNY 552,570,153.79, a significant increase from CNY 476,380,098.59 in 2023[68]. - The proportion of raw materials in the pharmaceutical industry’s operating costs decreased from 73.53% in 2023 to 62.05% in 2024, reflecting improved cost management[68]. - Financial expenses increased by 194.18% to ¥3,745,135.24, mainly due to a rise in interest expenses during the reporting period[74]. - R&D expenses decreased by 6.73% to ¥105,215,197.93, with no significant changes reported[74]. - The company reported an investment income of ¥32,419,272.15, accounting for 54.02% of total profit, primarily from equity method investments[84]. Governance and Compliance - The company has established a robust internal audit system to monitor and evaluate internal management effectively[148]. - The company has a complete independent business system, including R&D, production, and sales, without reliance on controlling shareholders[150]. - The company has adhered to various environmental protection laws and standards, ensuring compliance in its daily operations[191]. - The company has obtained all necessary environmental permits, including the "Pollutant Discharge Permit," for its subsidiaries[192]. - The company has implemented continuous improvements and refinements to its internal control systems in accordance with relevant laws and regulations[188]. Environmental Responsibility - The company has a wastewater discharge standard that complies with GB8978-1996, with a total discharge of 18 tons per day[196]. - The company paid an environmental protection tax of 8,753.08 yuan for the taxable pollutants including sulfur dioxide, nitrogen oxides, and smoke dust in 2024[199]. - The company has developed an emergency response plan for environmental pollution incidents, registered with local environmental authorities[198]. - The company’s boiler emissions are treated using magnesium oxide and SNCR methods to meet national standards[195]. - The company has received multiple environmental approvals and permits, including a wastewater discharge permit valid until December 2025[193]. Employee Engagement and Development - The company has implemented a comprehensive training plan focusing on enhancing core competitiveness and employee capabilities through a structured training system[179]. - The total number of employees at the end of the reporting period is 2,522, with 1,758 in the parent company and 764 in major subsidiaries[176]. - The professional composition includes 1,203 production personnel, 206 sales personnel, 747 technical personnel, 42 financial personnel, and 324 administrative personnel[176]. - The educational background of employees shows 4 with a doctorate, 117 with a master's degree, 857 with a bachelor's degree, 489 with an associate degree, and 1,055 with education below an associate degree[177]. - The company has established a performance evaluation and remuneration incentive system for directors and senior management based on their job responsibilities and performance indicators[185].

Revenue and Profit - The company's revenue for Q1 2025 was ¥205,027,782.58, a decrease of 16.93% compared to ¥246,819,438.23 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥28,845,105.91, representing a decline of 253.52% from a profit of ¥18,789,452.77 in the previous year[5] - Total revenue decreased to ¥205,027,782.58 from ¥246,819,438.23, a decline of approximately 17%[18] - Net profit turned negative at -¥29,795,441.26 compared to a profit of ¥17,414,092.70 in the previous period, indicating a significant decline[18] - Operating profit also fell to -¥35,207,091.55 from ¥18,914,975.05, marking a substantial decrease[18] - The total comprehensive income amounted to -29,795,441.26, down from 17,414,092.70 in the previous period[19] Earnings Per Share - Basic and diluted earnings per share were both -¥0.09, down 250.00% from ¥0.06 in the previous year[5] - The basic and diluted earnings per share were both -0.09, compared to 0.06 in the previous period[19] Cash Flow - The net cash flow from operating activities improved significantly to ¥86,305,192.39, a 341.32% increase from a negative cash flow of ¥35,763,547.76 in the same period last year[5] - Cash inflows from operating activities totaled 309,894,685.22, while cash outflows were 223,589,492.83[21] - The net cash flow from investing activities was -59,333,626.64, compared to -95,557,908.40 in the previous period[21] - Cash inflows from financing activities were 548,188,657.04, with cash outflows of 458,481,029.99, resulting in a net cash flow of 89,707,627.05[21] - The ending cash and cash equivalents balance was 672,160,767.37, up from 615,495,077.20 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,727,905,773.09, a decrease of 1.91% from ¥3,800,468,270.17 at the end of the previous year[5] - Total liabilities decreased to ¥1,592,613,755.20 from ¥1,636,313,285.80, a reduction of approximately 3%[15] - Owner's equity decreased to ¥2,135,292,017.89 from ¥2,164,154,984.37, a decline of about 1.3%[15] Expenses - Sales expenses decreased by 34.67% to ¥52,760,862.47 compared to ¥80,759,821.86 in the same period last year, mainly due to the impact of drug procurement policies[8] - Financial expenses increased by 165.74% to ¥4,377,685.71 from -¥6,659,002.31 in the previous year, primarily due to a significant reduction in interest income[8] - Research and development expenses decreased to ¥18,780,039.34 from ¥24,691,842.55, a reduction of approximately 24%[18] Government Subsidies and Other Income - The company received government subsidies amounting to ¥3,996,544.70, which were included in the current period's profit and loss[6] - Received cash from other operating activities increased to ¥63,055,036.01, a 233.16% increase compared to the previous period, mainly due to significant government subsidies and interest income from long-term loans[10] - Cash received from investment recoveries was ¥30,000,000.00, marking a 100% increase due to the redemption of financial products[10] - Cash received from investment income was ¥9,059,178.08, a 100% increase, resulting from cash dividends received from an associate company[10] Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,272, with the largest shareholder holding 39.10% of the shares[11] - The largest shareholder, Qin Jianfei, has pledged 36,000,000 shares, representing a significant portion of his holdings[11]